CBX

An increasing number of drug candidates made in China have been out-licensed. Here are the ones aimed for approval in foreign countries. ★ BL-B01D1, anti-EGFRxHER3 ADC,  SystImmune 2023.12  Announced in Ph3, BMS " $800 million in an upfront payment and up to $500 million in contingent near-term payments. SystImmune is eligible to receive additional payments of up to $7.1 billion contingent upon the achievement of certain development, regulatory and sales performance milestones for a total potential consideration of up to $8.4 billion. The companies will share certain global development expenses and profits and losses in the United States. Through its affiliates, SystImmune will retain exclusive development and commercialization rights in Mainland China, where Bristol Myers Squibb will receive a royalty on net sales. Outside the United States and Mainland China, SystImmune will receive a tiered royalty on net sales. The agreement is subject to customary clearance by antitrust regu

Here, we introduce several methods for following up on new drug updates in China: 1. Approval Information of Drugs Here we are going to introduce how to get the latest updates on the Chinese National Medical Products Administration ( NMPA ) website, including the new drug approval. Where to find the DRUG APPROVAL data Drug search page On the drug search page , we can input the name (Chinese or English) to get the approved drug list with the domestic and imported drugs selected. You can get the full details of the approval when you click the product link. Drug list Datails 2. IND Updates of New Drugs Here we will introduce how to search the new drug Investigational New Drug Application (IND) updates in China. Where to find the NEW DRUG IND data Navigation bar We can find that info on the China Center for Drug Evaluation (CDE)  website . Select the 受理品种信息 on the navigation bar. The new IND updates are here for you. You can search the specific products by entering the name in the 药品名称 or